April 29th, 2025 | 07:15 CEST
Coinbase, Defence Therapeutics, Palantir – Forward-looking decisions
The current trading week promises to be super exciting. In addition to possible surprise posts from Donald Trump on his Truth Social platform regarding punitive tariffs, the highlight of the reporting season is coming up. Around 800 companies will provide insights into their annual reports over the next few days, including heavyweights such as Coca-Cola and Mastercard, as well as tech giants Microsoft, Meta Platforms, and Qualcomm.
time to read: 3 minutes
|
Author:
Stefan Feulner
ISIN:
Coinbase | US19260Q1076 , DEFENCE THERAPEUTICS INC | CA24463V1013 , PALANTIR TECHNOLOGIES INC | US69608A1088
Table of contents:
"[...] In summary, there are many different healing processes that make us very confident that our drug has the ability to help many millions of people with a wide variety of causes of nervous system damage. [...]" Bill Radvak, CEO, NervGen Pharma
Author
Stefan Feulner
The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
He is passionate about analyzing a wide variety of business models and investigating new trends.
Tag cloud
Shares cloud
Defence Therapeutics – Consolidation complete
The US president's announcement of punitive tariffs on "Liberation Day" sent stock markets around the world reeling, with the biotech sector also being dragged down in the wake, presenting investors with another buying opportunity. Shares in Defence Therapeutics, a research company working to develop the next generation of vaccines and ADC products using its proprietary and patented Accum® platform, consolidated after a strong rise of around 237% to an interim high of CAD 1.66, closed the upward gap that had opened at CAD 0.85 and has since turned north again.
With the sustained break above the downward trend established in December at CAD 0.90, the path to the 200 EMA at CAD 1.02 would be clear in the short term. The next major resistance would then be at CAD 1.30. Both MACD and RSI gave a buy signal at a low level last week, indicating that there is still significant upside potential.
Accum® technology addresses a key problem in modern therapies: many active ingredients remain in cell compartments and do not reach their target location. Accum® enables more targeted release, increases efficacy by a factor of 10, and thus allows for lower dosages. Its cross-industry applicability, from cancer vaccines to mRNA therapies, opens up access to billion-dollar markets.
With patents until 2043, Defence has not only secured its technological leadership but also laid the foundation for licensing and recurring revenues. Dr. Elias Theodorou was recently introduced as the new COO. With 25 years of research expertise, he will play a key role in advancing the commercialization of the technology.
Coinbase – Buy signals generated
After a downward trend since January, Bitcoin rebounded from its interim low of USD 74,434 and dynamically regained the USD 90,000 mark last week. Compared to the stock market, Bitcoin & Co. have shown relative strength since Trump's tariffs were announced. Marking new highs again in the coming weeks is, therefore, not unlikely.
The crypto exchange Coinbase once again benefited from the rising prices. After confirming a double bottom at USD 146.12, the stock was able to start a new upward momentum and break through the USD 200 mark. The trend-following indicator MACD is at "Buy", while the relative strength index RSI is currently at a "Neutral" 61 points and still has significant upside potential.
The 100 and 200 EMAs are in the USD 220 range. A sustained break above the downward trend established since the beginning of December 2024, currently at USD 245, would already generate price targets beyond the USD 300 mark. Downward support is currently in the USD 180 range. A drop below this mark, on the other hand, would be a clear bearish sign.
PayPal – Revolutionary cooperation
Another reason for the upward swing in Coinbase shares was a forward-looking cooperation with the leading US payment provider PayPal, which could revolutionize digital payments in the future. The partnership aims to strengthen the distribution and functionality of the PayPal USD (PYUSD) stablecoin. The goal is to make it easier for consumers, businesses, and institutions to access digital currencies with the stability of USD-backed assets.
As part of the expanded collaboration, Coinbase users can buy, sell, and trade PYUSD without platform fees and redeem it at a 1:1 ratio against the US dollar on Coinbase platforms.
In addition, PayPal and Coinbase plan to work together on innovations to advance stablecoin-based solutions for global money transfers, particularly in the area of commerce. They also intend to explore new use cases for PYUSD in decentralized finance (DeFi) and on-chain platforms.
PayPal President and CEO Alex Chriss emphasized the importance of this partnership, which builds on a shared history of making cryptocurrencies more accessible to users. Brian Armstrong, CEO of Coinbase, highlighted that the partnership offers an opportunity to leverage PayPal's large consumer and merchant accounts base for the global adoption of stablecoins.
This new agreement builds on an earlier collaboration in 2021 that allowed Coinbase users to use PayPal accounts for instant funding of cryptocurrency purchases and fiat withdrawals.
PayPal USD is a stablecoin issued by Paxos Trust Company and is fully backed by US dollar deposits, US Treasury securities, and similar liquid assets. PYUSD can be traded at a fixed rate of USD 1.00 per token via PayPal and Venmo.
Cryptocurrencies continued their upward momentum last week. This allowed the Coinbase crypto exchange to regain the USD 200 mark. A revolutionary partnership with payment provider PayPal also provided positive impetus. Defence Therapeutics consolidated in line with the overall market correction, with indicators once again signaling a buy.
Conflict of interest
Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.
In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.
For this reason, there is a concrete conflict of interest.
The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.
Risk notice
Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.
The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.
The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.
